Therapy of systemic lupus erythematosus: new agents and new evidence

Bibliography

• CERVERA R, KHAMASHTA MA, FONT J et al.: Morbidity and mortality in systemic lupus erythematosus during a 5-year period: a multicenter prospective study of 1000 patients followed from 1990 to 1995. Medicine (1999) 78:167–175.
   PubMed Web of Science ®Google Scholar
• BOUMPAS DT, AUSTIN HA, VAUGHAN EM, YARBORO CH, KLIPPEL JH, BALOW JE: Risk for sustained amenor-rhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann. Intern. Med. (1993) 119:366–369.
   PubMed Web of Science ®Google Scholar
• GODFREY T, KHAMASHTA M, HUGHES GRV: Therapeutic advances in systemic lupus erythema-tosus. Curr. Op. Rheumatol. (1998) 10:435–441.
   PubMedGoogle Scholar
• •Recent in-depth review on SLE therapy.
   Google Scholar
• RAHMAN P, HUMPHREY-MURTO S, GLADMAN DD, UROWITZ MB: Cytotoxic therapy in systemic lupus erythematosus. Experience from a single center. Medicine (1997) 76:432–437.
   Google Scholar
• KIM MY, BUYON JP, PETRI M, SKOVRON ML, SHORE RE: Equivalence trials in SLE research: issues to consider. Lupus (1999) 8:620–626.
   PubMed Web of Science ®Google Scholar
• •Excellent paper addressing the need and characteristics of equivalence trials in SLE.
   Google Scholar
• STRAND V: Biologic agents and innovative interventional approaches in the management of systemic lupus erythematosus. Curr. Op. Rheumatol. (1999) 11:330–340.
   PubMedGoogle Scholar
• •Recent in-depth review on SLE therapy with many updated references.
   Google Scholar
• ALVAREZ-NEMEGYEI J, COBARRUBIAS-COBOS A, ESCALANTE-TRIAY F, SOSA-MUROZ J, MIRANDA JM, JARA LJ: Bromocriptine in systemic lupus erythematosus: a double-blind randomized, placebo-controlled study. Lupus (1998) 7:414–419.
   PubMed Web of Science ®Google Scholar
• DAVIS JC, MANZI S, YARBORO C et al.: Recombinant human DNase (rhDNase) in patients with lupus nephritis. Lupus (1999) 8:68–76.
   PubMed Web of Science ®Google Scholar
• •Small randomised controlled trial showing the safety of rhDNase.
   Google Scholar
• VAN VOLLENHOVEN RF, PARK JL, GENOVESE MC, WEST JP, MCGUIRE JL: A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus (1999) 8:181–187.
   PubMed Web of Science ®Google Scholar
• BOLETIS J, IOANNIDIS JPA, BOKI KA, MOUTSOPOULOS M: Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet (1999) 354:569–570.
   PubMed Web of Science ®Google Scholar
• GOURLEY MF, AUSTIN HA, SCOTT D et al.: Methylpredni-solone and cyclophosphamide, alone or in combina-tion, in patients with lupus nephritis. A randomized, controlled trial. Ann. Intern. Med. (1996) 125:549–557.
   PubMed Web of Science ®Google Scholar
• ••Randomised controlled trial showing the superiority ofcyclophosphamide-containing regimens for lupus nephritis.
   Google Scholar
• MEINAO IM, SATO El, ANDRADE LEC, FERRAZ MB, ATRA E: Controlled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus (1996) 5:237–241.
   PubMed Web of Science ®Google Scholar
• ••Randomised controlled trial showing the efficacy of chloro-quine in mild SLE.
   Google Scholar
• WALLACE DJ, GOLDFINGER D, PEPKOWITZ SH et al: Randomized controlled trial of pulse/synchronization cyclophosphamide/apheresis for proliferative lupus nephritis. J. Gun. Apheresis (1998) 13:163–166.
   PubMed Web of Science ®Google Scholar
• CARNEIRO JR, SATO El: Double-blind, randomized, placebo-controlled clinical trial of methotrexate in systemic lupus erythematosus. j Rheumatol (1999) 26:1275–1279.
   PubMed Web of Science ®Google Scholar
• ••Randomised controlled trial confirming the efficacy ofmethotrexate for moderate lupus.
   Google Scholar
• AUSTIN HA, KLIPPEL JH, BALOW JE et al.: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl. J. Med. (1986) 314:614–619.
   PubMed Web of Science ®Google Scholar
• BOUMPAS DT, AUSTIN HA, VAUGHAN EM et al.: Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet (1992) 340:741–745.
   PubMed Web of Science ®Google Scholar
• ILLEI GG, CRANE M, COLLINS L et al.: Long-term follow-up of patients with lupus nephritis (LN) treated with methylprednisolone or cyclophosphamide alone or in combination . Arthritis Rheum. (1999) 42:S166 (Abstract).
   Google Scholar
• THE CANADIAN HYDROXYCHLOROQUINE STUDY GROUP: A randomized study of the effect of withdrawing hydroxychloroquine sulphate in systemic lupus erythematosus. N Engl. J. Med. (1991) 324:150–154.
   PubMed Web of Science ®Google Scholar
• KHAMASHTA MA, RUIZ-IRASTORZA G, HUGHES GRV: Systemic lupus erythematosus flares during pregnancy. Rheum. Dis. Clin. North Am. (1997) 23:15–30.
   PubMed Web of Science ®Google Scholar
• VAN VOLLENHOVEN RF, ENGLEMAN EG, MCGUIRE JL:Dehydroepiandrosterone in systemic lupus erythema-tosus. Results of a double-blind, placebo-controlled, randomized clinical trial. Arthritis Rheum. (1995) 12:1826–1831.
   Google Scholar
• ALTMAN DG: Relation between two continuous variables. In: Practical statistics for medical research. Altman DG (Ed.) Chapman & Hall, London, UK (1990:277–324.
   Google Scholar
• GANSAUGE S, BREIBART A, RINALDI N, SCHWARTZ-EYWILL M: Methotrexate in patients with moderate in systemic lupus erythematosus (exclusion of renal and central nervous system disease). Ann. Rheum. Dis. (1997) 56:382–385.
   PubMed Web of Science ®Google Scholar
• CACCAVO D, LAGANA B, MITTERHOFER AP et al.: Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum. (1997) 40:27–35.
   PubMed Web of Science ®Google Scholar
• •The largest prospective series of lupus patients treated with cyclosporin.
   Google Scholar
• MANGER K, KALDEN JR, MANGER B: Cyclosporin A inthe treatment of systemic lupus erythematosus: results of an open clinical study. Br. J. Rheumatol. (1996) 35:669–675.
   PubMedGoogle Scholar
• TAM LS, LI EK, LEUNG CB et al.: Long-term treatment oflupus nephritis with cyclosporin A. Q. J. Med. (1998) 91:573–580.
   Google Scholar
• •Prospective series showing the utility of cyclosporin in proliferative lupus nephritis.
   Google Scholar
• DOSTAL C, TESAR V, RYCHLIK I et al.: Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus (1998) 7:29–36.
   PubMed Web of Science ®Google Scholar
• SUGIYAMA M, OGASAWARA H, KANEKO H et al.: Effect of extremely low dose cyclosporine treatment on the thrombocytopoenia in systemic lupus erythematosus. Lupus (1998) 7:53–56.
   PubMed Web of Science ®Google Scholar
• DE MATTOS AM, OLYAEI AJ, BENNET WM: Nephrotox-i city of immunosuppressive drugs: long-term consequences and challenges for the future. Am. J. Kidney Dis. (2000) 35:333–346.
   PubMed Web of Science ®Google Scholar
• KIBERD B, MACDONALD A: Mycophenolate and glomerular disease. Am. J. Kidney Dis. (1998) 31:364–365.
   PubMed Web of Science ®Google Scholar
• BRIGGS WA, CHOI MJ, SCHEEL PJ: Successful mycophe-nolate mofetil treatment of glomerular disease. Am. J. Kidney Dis. (1998) 31:213–217.
   PubMed Web of Science ®Google Scholar
• GLICKICH D, ACHARYA A: Mycophenolate mofetil for lupus nephritis refractory to intravenous cyclophos-phamide. Am. J. Kidney Dis. (1998) 32:318–322.
   PubMed Web of Science ®Google Scholar
• DOOLEY MA, COSIO FG, NACHMAN PH et al: Mycophe-nolate mofetil therapy in lupus nephritis: clinical observations. J. Am. Soc. Nephrol. (1999) 10:833–839.
   PubMed Web of Science ®Google Scholar
• •Largest series of patients with lupus nephritis treated with MMF.
   Google Scholar
• GAUBITZ M, SCHORAT A, SCHOTTE H, KERN P, DOMSCHKE W: Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus (1999) 8:731–736.
   PubMed Web of Science ®Google Scholar
• •Another group of severe SLE receiving MMF.
   Google Scholar
• PETRI M: Mycophenolate mofetil treatment of systemiclupus erythematosus (abstract). Arthritis Rheum. (1999) 42:S303.
   Web of Science ®Google Scholar
• MENDOKA LLF, TYNDALL A: Bone marrow transplan-tation in the treatment of autoimmune diseases: evolving concepts and early experience. Lupus (1997) 6:561–563.
   PubMed Web of Science ®Google Scholar
• SHERER Y, SHOENFELD Y: Stem cells transplantation - a cure for autoimmune disease. Lupus (1998) 7:137–140.
   PubMed Web of Science ®Google Scholar
• MARMONT AM: Intense immunosuppression and stem cell transplantation or rescue for severe systemic lupus erythematosus. Lupus (1999) 8:256–257.
   PubMed Web of Science ®Google Scholar
• MARMONT AM, VAN LINT MT, GUALANDI F, BACIGALUPO A: Autologous marrow stem cell transplantation for severe systemic lupus erythema-tosus of long duration. Lupus (1997) 6:545–548.
   PubMed Web of Science ®Google Scholar
• BURT R, TRAYNOR A, RAMSEY-GOLDMAN R: Hemato-poietic stem-cell transplantation for systemic lupus erythematosus. N Engl. J. Med. (1997) 337:1777–1778.
   PubMed Web of Science ®Google Scholar
• MUSSO M, PORRETTO F, CRESCIMANNO A et al: Autolo-gous peripheral blood stem and progenitor (CD34+) cell transplantation for systemic lupus erythematosus complicated by Evans syndrome. Lupus (1998) 7:492–494.
   PubMed Web of Science ®Google Scholar
• BURT RB, TRAYNOR AE, POPE R et al.: Treatment of autoimmune diseases by intense immunosuppressive conditioning and autologous hematopoietic stem cell transplantation. Blood (1998) 92:3505–3514.
   PubMed Web of Science ®Google Scholar
• FOUILLARD L, GORIN NC, LAPORTE JPH, LEON A, BRANTUS JF, MIOSSEC P: Control of severe systemic lupus erythematosus after high-dose immunosup-pressive therapy and transplantation of CD34+ purified and autologous stem cells from peripheral blood. Lupus (1999) 8:320–323.
   PubMed Web of Science ®Google Scholar
• TRAYNOR AE, SCHROEDER J, ROSA RM et al.: Stem cell transplantation for resistant lupus (abstract). Arthritis Rheum. (1999) 42:S170.
   Web of Science ®Google Scholar
• HIEPE F, ROSEN O, THIEL A et al.: Successful treatment of refractory systemic lupus erythematosus (SLE) by autologous stem cell transplantation (ASCT) with in vivo immunoablation and ex vivo depletion of mononuclear cells. Arthritis Rheum. (1999) 42:S170.
   Web of Science ®Google Scholar
• BRODSKY RA, PETRI M, SMITH BD et al: Immunoabla-tive high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann. Intern. Med. (1998) 129:1031–1035.
   PubMed Web of Science ®Google Scholar
• •First report of successful immunoablative treatment without subsequent marrow transplantation.
   Google Scholar
• PETRI M, JONES A, BRODSKY R: High-dose immunoabla-tive cyclophosphamide in SLE (abstract). Arthritis Rheum. (1999) 42:S170.
   Google Scholar
• TYNDALL A, GRATHVVOHL A: Blood and marrow stem cell transplants in autoimmune disease. A consensus report on behalf of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow transplantation (EBMT). Br. J. Rheumatol. (1997) 36:390–392.
   Google Scholar
• CORRAL LG, KAPLAN G: Immunomodulation by thalidomide and thalidomide analogues. Ann. Rheum. Dis. (1999) 58 (Suppl. I):1107–1113.
   Google Scholar
• RAJE N, ANDERSON K: Thalidomide - a revival story. N Engl. J. Med. (1999) 341:1606–1609.
   PubMed Web of Science ®Google Scholar
• STEVENS RJ, ANDUJAR C, EDWARDS CJ et al.: Thalido-mide in the treatment of cutaneous manifestations of lupus erythematosus: experience in sixteen consecu- tive patients. Br. J. Rheumatol. (1997) 36:353–359.
   PubMedGoogle Scholar
• DUONG DJ, SPIGEL GT, MOXLEY RT, GASPARI AA: American experience with low-dose thalidomide therapy for severe cutaneous lupus erythematosus. Arch. Dermatol. (1999) 135:1079–1087.
   PubMed Web of Science ®Google Scholar
• ORDI J, CORTES F, MARTINEZ N, MAURI M, DETORRES I,VILARDELL M: Thalidomide induces amenorrhea in patients with lupus disease. Arthritis Rheum. (1998) 41:2273–2275.
   PubMed Web of Science ®Google Scholar
• SATO El, ASSIS LS, LOURENZI VP, ANDRADE LE: Long-term thalidomide use in refractory cutaneous lesions of systemic lupus erythematosus. Rev. Assoc. Med. Bras. (1998) 44:289–293.
   PubMedGoogle Scholar
• DAVIS JC, AUSTIN H, BOUMPAS D et al.: A pilot study of 2-chloro-2'-deoxyadenosine in the treatment of systemic lupus erythematosus-associated glomeru-lonephritis. Arthritis Rheum. (1998) 41:335–343.
   PubMed Web of Science ®Google Scholar
• KONTOGIANNIS V, LANYON PC, POWELL RJ: Cladribine in the treatment of systemic lupus erythematosus nephritis. Ann. Rheum. Dis. (1999) 58:653.
   PubMed Web of Science ®Google Scholar
• HOUSSIAU FA, DELANNOY A, DEVOGELAER JP: Paradoxical immunologic effects of 2-CdA therapy: comment on the article by Davis et al Arthritis Rheum. (1998) 41: 1704-1705.
   Google Scholar
• LEVY Y, SHERER Y, AHMED A et al.: A study of 20 SLE patients with intravenous immunoglobulin - clinical and serologic response. Lupus (1999) 8:705–712.
   PubMed Web of Science ®Google Scholar
• •Large series and up-to-date review of iv. Ig for the treatment of SLE.
   Google Scholar
• SCHROEDER JO, ZEUNER RA, EULER HH, LOFFLER H: High dose intravenous immunoglobulins in systemic lupus erythematosus: clinical and serological results of a pilot study. J. Rheumatol. (1996) 23:71–75.
   PubMed Web of Science ®Google Scholar
• DE PITA O, BELLUCCI AM, RUFFELLI M, GIRARDELLI CR, PUDDU P: Intravenous immunoglobulin therapy is not able to efficiently control cutaneous manifestations in patients with lupus erythematosus. Lupus (1997) 6:415–417.
   PubMed Web of Science ®Google Scholar
• Outbreak of hepatitis C associated with intravenous immunoglobulin administration-United States, October 1993-June 1994. MMWR (1994) 43:505–509.
   PubMedGoogle Scholar
• JORDAN SC: Intravenous 7-globulin therapy in systemic lupus erythematosus and immune complex disease. Clin. Immunol. Immunopathol (1989) 53:164–169.
   Google Scholar
• HASHKES PJ, LOVELL DJ: Vasculitis in systemic lupus erythematosus following intravenous immuno-globulin therapy. Clin. Exp. Rheumatol. (1996) 14:673–675.
   PubMed Web of Science ®Google Scholar
• DUDDRIDGE M, POWELL RJ: Treatment of severe and difficult cases of systemic lupus erythematosus with tacrolimus. A report of three cases. Ann. Rheum. Dis. (1997) 56:690–692.
   PubMed Web of Science ®Google Scholar
• BOUMPAS DT, TASSIULAS 10, FLEISHER TA et al.: A pilot study of low-dose fludarabine in membranous nephropathy refractory to therapy. Clin. Nephrol. (1999) 52:67–75.
   Google Scholar
• VIALLARD JF, MERCIE P, FAURE I, PELLEGRIN JL, LENG B:Successful treatment of lupus with fludarabine. Lupus (1999) 8:767–769.
   PubMed Web of Science ®Google Scholar
• BLANCO R, MARTINEZ-TABOADA VM, RODRIGUEZ-VALVERDE V, SANCHEZ-ANDRADE Z, GONZALEZ-GAY MA: Successful therapy with danazol in refractory autoimmune thrombocytopoenia associated with rheumatic diseases. Br. J. Rheumatol. (1997) 36:1095–1099.
   PubMedGoogle Scholar
• •Interesting report on the use of danazol in seven patients with thrombocytopoenia secondary to autoimmune diseases, including four patients with SLE.
   Google Scholar
• GALINDO-RODRIGUEZ G, ESQUIVEL G, BUSTAMANTE R,LAVALLE C, AVINA-ZUBIETA A: Efficacy of pentoxifyl-line in the treatment of refractory nephrotic syndrome in lupus nephritis (abstract). Arthritis Rheum. (1999) 42:S214.
   Web of Science ®Google Scholar
• YOSHIDA T, KAMEDA H, ICHIKAWA Y, TOJO T, HOMMA M: Improvement of renal function with a selective thromboxane A2 synthetase inhibitor, DP-1904, in lupus nephritis. J. Rheumatol. (1996) 23:1719–1724.
   PubMed Web of Science ®Google Scholar
• WEISMAN MH, BLUESTEIN HG, BERNER CM, DE HAANHA: Reduction in circulating dsDNA antibody titer after administration of UP 394. J. Rheumatol (1997) 24:314–318.
   PubMed Web of Science ®Google Scholar
• DATTA SK, KALLED SL: CD4O-CD40 Ligand interactionin autoimmune disease. Arthritis Rheum. (1997) 40:1735–1745.
   PubMed Web of Science ®Google Scholar
• HARIGAI M, HARA M, FUKASAWA C et al: Responsive-ness of peripheral blood B cells to recombinant CD40 ligand in patients with systemic lupus erythematosus. Lupus (1999) 8:227–233.
   PubMed Web of Science ®Google Scholar
• DAVIS JC, TOTORITIS MC, SKLENAR TA, WOFSY D: Results of a Phase I, single-dose, dose-escalating trial of a humanized anti-CD4OL monoclonal antibody (IDEC-131) in patients with systemic lupus erythema-tosus. Arthritis Rheum. (1999) 42:S281 (Abstract).
   Google Scholar